Dragonfly Therapeutics是一家处于临床阶段的生物制药公司,成立于2015年,该公司的TriNKET™(Tri-specific NK cell Engagement Therapies)平台可以提供一种三特异性NK细胞接合剂,这是一种NK细胞募集免疫疗法,通过链接NK细胞与肿瘤细胞表面的蛋白来激活NK细胞,使其直接攻击肿瘤细胞或协助T细胞和B细胞进行抗癌免疫反应。 两...
近日,Dragonfly Therapeutics公司与默沙东(MSD)公司达成了协议,将投入6.95亿美元来支持TriNKET研发的实体瘤癌症免疫疗法进行开发和市场推广。 TriNKET(Tri-specific NK cell Engagement Therapies)是Dragonfly公司独有的技术平台,该技术可以通过对自然杀伤(NK)细胞的控制和调节,来增强肿瘤免疫疗法的适用范围与疗效。 伴随着...
Gasteiger, G. and Rudensky, A. Y., Interactions between innate and adaptive lymphocytes.Nat Rev Immunol 2014. 14: 631-639. Cooper, M. A., Fehniger, T. A. and Caligiuri, M. A., The biology of human natural killer-cell...
TriNKE(Tri-specific;NK cell Engagement Therapies/三特异性;自然杀伤细胞接合器疗法)平台的作用机制主要是通过提供癌细胞与免疫系统细胞(包括NK细胞本身、T细胞、B细胞和其他有助于攻击和杀死癌症的细胞)之间的主动连接进行运作,极大地提高了自然杀伤细胞—NK细胞的免疫能力。 12月1日,默沙东(MSD)从Dragonfly Therapeu...
To use Siglec-7 engagement as an OC-specific strategy, we engineered an NK cell engager (NKCE) to simultaneously engage NK cells through Siglec-7, and OC targets through FSHR. The NKCE demonstrated robust in vitro killing of FSHR+ OC, controlled tumors, and improved survival in OC-...
NK Cell Killing Strategies for Immunotherapy Several strategies aim to improve tumor reduction via NK cell killing: Enhancing NK cell killing performance by augmenting NK cell function Antibody-dependent cellular cytotoxicity (ADCC) NK cell engagement via bi-specific molecules ...
该公司的NK细胞治疗主要基于NantKwest专有的NK-92(aNK)主细胞库,经过工程改造后使其表达高亲和力CD16受体,从而使其可以直接结合先前与癌细胞结合的单克隆抗体,通过抗体介导的ADCC作用来增强对肿瘤细胞的杀伤作用。其产品PD-L1.t-haNK,是在此基础上增加了靶向PD-L1的CAR。
(NKTROG+) and NK cell hyporesponsiveness. This phenomenon could be offset by a dual-CAR system incorporating both an activating CAR against the cognate tumor antigen and an NK self-recognizing inhibitory CAR that transferred...
2018年10月,与默沙东达成了一项高达6.95亿美元的合作协议,联合对通过Dragonfly公司独有的技术平台TriNKET(Tri-specific NK cell Engagement Therapies)研发的实体瘤癌症免疫疗法进行开发和市场推广。 2018年12月13日,Celgene公司(2019年被BMS收购)以总计2400万美元的预付款、未来的里程碑和特许权使用费,获得Dragonfly的2...
When the NK-cell via its CD16A receptor is engaged by the tandem diabody with a CD30-positive tumor cell (via its CD30 antigen) it forms an immunological synapse, which generates a strong activating signal. Simultaneous engagement of the tandem diabody with the NK-cell via its CD16A recep...